A Phase 2 interventional study of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Chronic Hepatitis C, Hepatitis C (HCV) and Hepatitis C Genotype 1a, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2017-10-31.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing ombitasvir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. ombitasvir · Hepatitis C, Chronic.
Among the 19 studies testing ombitasvir in Hepatitis C, Chronic, this one is the 13th largest by enrollment, is one of 7 that started in 2015, is one of 7 in phase 2, and was the 15th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 19 studies testing ombitasvir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
ombitasvir: first FDA approval 2014 (VIEKIRA PAK (COPACKAGED)), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 11 · Phase 4 1
First in 2011; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 148 across the 19 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 5 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
83 studies in Hepatitis C, Chronic by AbbVie: none open now, none under way, none of them phase 3. Of 82 finished, 74 (90%) have results posted.
Among the 83 studies in Hepatitis C, Chronic by AbbVie, this one is the 44th largest by enrollment of the 58 interventional ones that give a count, is one of 25 that started in 2015, is one of 13 in phase 2, and was the 36th registered.
AbbVie’s Hepatitis C, Chronic studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing ombitasvir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 83 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of ribavirin on second phase plasma hepatitis C virus (HCV) ribonucleic acid (RNA) decline in participants who receive ombitasvir/ABT-450/ritonavir and dasabuvir with full dose ribavirin, low dose ribavirin or without ribavirin for 2 weeks in treatment-naive HCV genotype (GT) 1a-infected adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) for 12 weeks and weight-based ribavirin (1000 mg or 1200 mg split BID) for the last 10 weeks.
Drug: Ombitasvir/ABT-450/Ritonavir · Drug: Dasabuvir · Drug: Ribavirin (RBV)
Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and weight-based ribavirin (1000 mg or 1200 mg split BID) for 12 weeks.
Drug: Ombitasvir/ABT-450/Ritonavir · Drug: Dasabuvir · Drug: Ribavirin (RBV)
Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and 600 mg ribavirin once daily for 12 weeks.
Drug: Ombitasvir/ABT-450/Ritonavir · Drug: Dasabuvir · Drug: Ribavirin (RBV)
Drug pages: Ombitasvir · Paritaprevir · Ritonavir
Ombitasvir/ABT-450/ritonavir combination tablets
Also known as: ABT-267/ABT-450/ritonavir
Dasabuvir tablets
Also known as: ABT-333
Ribavirin tablets
Slope of the Second Phase Decline in Plasma HCV Ribonucleic Acid (RNA) Levels During Treatment
HCV viral kinetics in plasma during therapy were modeled through non-linear mixed effect models, including a rapid first phase of initial decline and a slower second phase decline. The slope of the second phase decline was estimated for each treatment arm.
Time frame: From Week 0 to Week 2
This study was conducted at one clinic in France and one clinic in the United States. Participants were treatment-naïve adults with hepatitis C virus (HCV) genotype (GT)1a infection without cirrhosis.
| Milestone | Arm A: Ribavirin Full Dose for Last 10 Weeks | Arm B: Ribavirin Full Dose for 12 Weeks | Arm C: Ribavirin Low-dose for 12 Weeks |
|---|---|---|---|
| Started | 21 | 19 | 6 |
| Completed | 19 | 18 | 6 |
| Not completed | 2 | 1 | 0 |
| Withdrew: Non-compliance | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
HCV viral kinetics in plasma during therapy were modeled through non-linear mixed effect models, including a rapid first phase of initial decline and a slower second phase decline. The slope of the second phase decline was estimated for each treatment arm.
| 1/day | Arm A: Ribavirin Full Dose for Last 10 Weeks | Arm B: Ribavirin Full Dose for 12 Weeks | Arm C: Ribavirin Low-dose for 12 Weeks |
|---|---|---|---|
| Slope of the Second Phase Decline in Plasma HCV Ribonucleic Acid (RNA) Levels During Treatment | 0.0036 (0.0006 to 0.0128) | 0.0046 (-0.0003 to 0.0155) | 0.0051 (0.0031 to 0.0076) |
Collected over From first dose of study drug until 30 days after last dose; up to 16 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Ribavirin Full Dose for Last 10 Weeks | — | 1/21 (4.8%) | 17/21 (81%) |
| Arm B: Ribavirin Full Dose for 12 Weeks | — | 0/19 (0%) | 16/19 (84.2%) |
| Arm C: Ribavirin Low-dose for 12 Weeks | — | 0/6 (0%) | 6/6 (100%) |
| Event | Arm A: Ribavirin Full Dose for Last 10 Weeks | Arm B: Ribavirin Full Dose for 12 Weeks | Arm C: Ribavirin Low-dose for 12 Weeks |
|---|---|---|---|
| DEPRESSIONPsychiatric disorders | 1/21 | 0/19 | 0/6 |
| DRUG DEPENDENCEPsychiatric disorders | 1/21 | 0/19 | 0/6 |
| Event | Arm A: Ribavirin Full Dose for Last 10 Weeks | Arm B: Ribavirin Full Dose for 12 Weeks | Arm C: Ribavirin Low-dose for 12 Weeks |
|---|---|---|---|
| PROCEDURAL PAINInjury, poisoning and procedural complications | 7/21 | 5/19 | 5/6 |
| DYSPEPSIAGastrointestinal disorders | 0/21 | 2/19 | 3/6 |
| FATIGUEGeneral disorders | 5/21 | 7/19 | 2/6 |
| ANAEMIABlood and lymphatic system disorders | 4/21 | 4/19 | 2/6 |
| DRY MOUTHGastrointestinal disorders | 1/21 | 1/19 | 2/6 |
| NAUSEAGastrointestinal disorders | 3/21 | 3/19 | 2/6 |
| HYPERBILIRUBINAEMIAHepatobiliary disorders | 2/21 | 0/19 | 2/6 |
| BACK PAINMusculoskeletal and connective tissue disorders | 2/21 | 1/19 | 2/6 |
| RASHSkin and subcutaneous tissue disorders | 0/21 | 1/19 | 2/6 |
| PRURITUSSkin and subcutaneous tissue disorders | 3/21 | 6/19 | 1/6 |
| Age, Continuous(years) | Arm A: Ribavirin Full Dose for Last 10 Weeks | Arm B: Ribavirin Full Dose for 12 Weeks | Arm C: Ribavirin Low-dose for 12 Weeks | Total |
|---|---|---|---|---|
| Mean | 44.9 ± 11.96 | 46.0 ± 12.78 | 36.7 ± 15.79 | 44.3 ± 12.88 |
| Age, Customized(Participants) | Arm A: Ribavirin Full Dose for Last 10 Weeks | Arm B: Ribavirin Full Dose for 12 Weeks | Arm C: Ribavirin Low-dose for 12 Weeks | Total |
|---|---|---|---|---|
| < 55 years | 17 | 14 | 5 | 36 |
| ≥ 55 - 65 years | 4 | 5 | 1 | 10 |
| ≥ 65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Arm A: Ribavirin Full Dose for Last 10 Weeks | Arm B: Ribavirin Full Dose for 12 Weeks | Arm C: Ribavirin Low-dose for 12 Weeks | Total |
|---|---|---|---|---|
| Female | 11 | 12 | 4 | 27 |
| Male | 10 | 7 | 2 | 19 |
| Race/Ethnicity, Customized(Participants) | Arm A: Ribavirin Full Dose for Last 10 Weeks | Arm B: Ribavirin Full Dose for 12 Weeks | Arm C: Ribavirin Low-dose for 12 Weeks | Total |
|---|---|---|---|---|
| White | 16 | 14 | 4 | 34 |
| Black of African American | 4 | 3 | 1 | 8 |
| Asian | 0 | 0 | 0 | 0 |
| American Indian or Alaskan Native | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Mutli Race | 1 | 2 | 1 | 4 |
No study locations are listed for this record.
Ran from Jun 2015 to primary completion in Apr 2016, 10 months.
Results were first posted in May 2017, 1 year 1 month after primary completion.
Of 28 industry-sponsored phase 2 interventional studies under Hepatitis C, Chronic, half reached primary completion within 16 months of starting (the median); a quarter within 10 and three quarters within 28. This study's 10 months is below that.
Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir · Ribavirin